FOLH1 and metastatic prostate carcinoma: This multicenter real-world study suggests that PSMA-guided focal therapy combined with darolutamide-based triplet therapy achieves a high rate of deep PSA responses in selected patients with metastatic prostate cancer while maintaining favorable safety and tolerability.